Acalabrutinib Maleate

證據等級: L5

預測適應症: 0 個

ACALABRUTINIB MALEATE: Repurposing Evaluation — Insufficient Data to Complete Full Assessment

One-Sentence Summary

Acalabrutinib maleate is a targeted anticancer agent (BTK inhibitor) currently registered in Malaysia, indicated for haematological malignancies such as chronic lymphocytic leukaemia and mantle cell lymphoma. However, no TxGNN predictions were generated in this Evidence Pack due to missing DrugBank ID mapping, and critical data fields — including approved indication text, mechanism of action, and safety warnings — are absent. A complete repurposing evaluation cannot proceed until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available in current data
Predicted New Indication	No predictions generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — No predictions run yet
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why No Prediction Is Available

The TxGNN repurposing pipeline requires a valid DrugBank ID to locate the drug node within the knowledge graph and compute drug–disease association scores. For this submission, drugbank_id is null, which means:

The drug could not be anchored in the TxGNN knowledge graph.
Neither the knowledge graph (KG) method nor the deep learning (DL) method produced candidate scores.
Without a scored candidate list, no ranked predicted indications can be reported.

Additionally, the mechanism of action (MOA) data is absent, preventing any mechanistic plausibility analysis even if a candidate indication were identified manually.

Acalabrutinib is known from published literature to be a second-generation, covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a central role in B-cell receptor signalling, making it relevant not only to its approved haematological indications but potentially to autoimmune and inflammatory conditions. However, these insights cannot be formally incorporated into a TxGNN report without completing the pipeline.

Malaysia Market Information

The drug is confirmed as marketed in Malaysia (1 active registration via NPRA). However, the detailed licence record returned was empty — authorization number, product name, dosage form, and approved indication text were all absent from this Evidence Pack.

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not returned by query)	(Not returned)	(Not returned)	(Not returned)

Note: NPRA query log confirms 1 result was found (query ID 1, status: success). The empty fields suggest a data extraction or parsing issue in the current pipeline run, not an absence of registration.

Cytotoxicity

Acalabrutinib is an antineoplastic targeted therapy. The following applies pending full package insert retrieval:

Item	Content
Cytotoxicity Classification	Targeted therapy — covalent BTK inhibitor
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Low (typical for oral small-molecule targeted agents)
Monitoring Items	CBC with differential, liver function tests, renal function
Handling Protection	Follow institutional cytotoxic drug handling protocols

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline did not produce any scored indications due to a missing DrugBank ID, and all safety and indication details from the regulatory record are absent — this Evidence Pack does not contain sufficient data to support a repurposing evaluation.

To proceed, the following is needed:

Resolve DrugBank ID mapping: Query DrugBank for “acalabrutinib” (the free base INN); the maleate salt form may not match directly. Expected ID: DB12116. Re-run scripts/run_kg_prediction.py after mapping.
Re-parse NPRA licence record: The NPRA query returned 1 result but all fields are empty. Review the raw response in data/raw/malaysia_fda_drugs.json and fix the field extraction in scripts/process_fda_data.py.
Retrieve MOA from DrugBank: Once the DrugBank ID is confirmed, pull pharmacodynamics, mechanism-of-action, and categories fields via the DrugBank API.
Download package insert PDF: Obtain the NPRA-approved package insert to extract approved indications, key warnings, and contraindications. This is flagged as a Blocking data gap (DG001).
Re-run Evidence Pack generation after the above four items are completed to produce a full L1–L5 evidence-graded report.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.